Skip to content

Viridian Therapeutics

US · VRDN #2731 by market cap Listed 1970
29.96 -1.48 -4.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 7.26 Expensive vs history 76th percentile
5-year average 6.00 · #436 of 514 in Biotechnology
P/E ratio -8.02 Cheap vs history 12th percentile
5-year average -4.91 · forward -11.97
P/S ratio 133.25 Cheap vs history 21st percentile
5-year average 1,839.27 · forward 11.41 · #302 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Viridian Therapeutics (VRDN) 3.40B -7.78 7.05 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value42.91 Economic moatNone UncertaintyVery High

Trading 43.2% below Morningstar's fair value estimate.

Fair value

Viridian Therapeutics Inc earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 28% discount to our quantitative fair value estimate of $42.91 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet strengthens our estimated fair value. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's long term debt to assets ratio of 0.2 falls in the top 30% globally. The firm has a high level of long-term debt relative to its asset base, which can signal significant investment in the business or a pending merger. In either case, it may suggest future growth in cash flows. We believe this is a sign that shares could be cheap.

The firm's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 3.4, a core component of valuation, falls in the bottom 40% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. This characteristic further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Viridian Therapeutics discussion 0 comments

Add a comment